Search

Triclabendazole

[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola … Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use.

Moxaverine

Moxaverine has been investigated for the treatment of Retina, Ocular Physiology, and Regional Blood Flow.

Platinum

Platinum is under investigation for the treatment of Metastatic Breast Cancer, Non-small Cell Lung Cancer, Gastric Large Cell Neuroendocrine Carcinoma, Colorectal Large Cell Neuroendocrine Carcinoma, and

Losmapimod

Losmapimod has been investigated for the prevention of Chronic Obstructive Pulmonary Disease.

ORE-1001

It is an ACE2 inhibitor.

Seviteronel

Seviteronel has been used in trials studying the treatment of CRPC, Prostate Cancer, and Castration-resistant Prostate Cancer.

Luspatercept

Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1. … [A187835] Luspatercept's novel mechanism of action, then, is uniquely suited for the treatment of conditions in which late-stage erythropoiesis is defective, such as beta thalassemia and other myelodysplastic

LY-2608204

LY2608204 has been used in trials studying the treatment of Diabetes Mellitus, Type 2.

Verubecestat

Verubecestat is Merck’s investigational oral β-site amyloid precursor protein cleaving enzyme (BACE1 or β secretase) inhibitor. … In the study, administration of Verubecestat at doses of 12, 40 and 60 mg resulted in a dose-dependent and sustained reduction in the levels of Ab40, a measure of BACE1 activity, in CSF from baseline of

Simendan